DAVID DAWES: Open Payments
NPI 1255383501 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$795 in 26 payments from 10 companies in 2025. Trend: 2023 $1,469 · 2024 $440 · 2025 $795
Food & beverage: $795
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $263 |
| E.R. Squibb & Sons, L.L.C. | 3 | $140 |
| Neurocrine BioSciences, Inc. | 1 | $94 |
| ABBVIE INC. | 4 | $83 |
| Janssen Pharmaceuticals, Inc | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
Products named: REXULTI, COBENFY, INGREZZA, VRAYLAR, INVEGA SUSTENNA, UZEDY, CAPLYTA, ERZOFRI EXTENDED-RELEASE.
Industry payments across LA — which companies pay providers there.
